Prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer

Kent Kanao, Toshiki Ito, Kiyoshi Takahara, Ryosuke Ando, Takahiro Yasui, Ryoichi Shiroki, Hideaki Miyake, Makoto Sumitomo

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The objective of this study was to categorize prostate-specific antigen (PSA) response during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) into different patterns and to investigate the prognostic impact of the PSA response patterns. METHODS: We reviewed data from patients with mCRPC who had been treated with cabazitaxel therapy at four institutions belonging to Tokai Urologic Oncology Research Seminar. Patients eligible for this study had received at least three cycles of cabazitaxel treatment at three- or four-week intervals. The PSA response patterns were categorized as primary resistance (PR), response (RE), stabilization (ST), and fluctuating (FL). The overall survival (OS) was compared among the patterns. RESULTS: Data from a total of 50 patients were analyzed in this study. The number of patients exhibiting PR, RE, ST and FL patterns were 18 (36%), 14 (28%), 12 (24%) and 6 (12%), respectively. The median (95% CI) OS of patients with PR and RE patterns was 10.7 (5.6-15.9) and 14.9 (6.8-23.0) months, respectively, and was not reached for patients with ST and FL patterns. The OS of patients with the FL pattern was significantly better than that of patients with PR (P = 0.012) and RE (P = 0.010) patterns. CONCLUSION: There were some patients whose PSA were fluctuating during cabazitaxel therapy in patients with mCRPC. Because the prognosis of such patients was relatively good, the judgment to discontinue the cabazitaxel therapy after PSA rise followed by decrease should be made prudently.

Original languageEnglish
Pages (from-to)1043-1048
Number of pages6
JournalJapanese journal of clinical oncology
Volume49
Issue number11
DOIs
Publication statusPublished - 18-12-2019

Fingerprint

Castration
Prostate-Specific Antigen
Prostatic Neoplasms
Therapeutics
Survival
cabazitaxel

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Kanao, Kent ; Ito, Toshiki ; Takahara, Kiyoshi ; Ando, Ryosuke ; Yasui, Takahiro ; Shiroki, Ryoichi ; Miyake, Hideaki ; Sumitomo, Makoto. / Prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer. In: Japanese journal of clinical oncology. 2019 ; Vol. 49, No. 11. pp. 1043-1048.
@article{43efd7d904194c0aaa6709e81ebcdfce,
title = "Prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer",
abstract = "BACKGROUND: The objective of this study was to categorize prostate-specific antigen (PSA) response during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) into different patterns and to investigate the prognostic impact of the PSA response patterns. METHODS: We reviewed data from patients with mCRPC who had been treated with cabazitaxel therapy at four institutions belonging to Tokai Urologic Oncology Research Seminar. Patients eligible for this study had received at least three cycles of cabazitaxel treatment at three- or four-week intervals. The PSA response patterns were categorized as primary resistance (PR), response (RE), stabilization (ST), and fluctuating (FL). The overall survival (OS) was compared among the patterns. RESULTS: Data from a total of 50 patients were analyzed in this study. The number of patients exhibiting PR, RE, ST and FL patterns were 18 (36{\%}), 14 (28{\%}), 12 (24{\%}) and 6 (12{\%}), respectively. The median (95{\%} CI) OS of patients with PR and RE patterns was 10.7 (5.6-15.9) and 14.9 (6.8-23.0) months, respectively, and was not reached for patients with ST and FL patterns. The OS of patients with the FL pattern was significantly better than that of patients with PR (P = 0.012) and RE (P = 0.010) patterns. CONCLUSION: There were some patients whose PSA were fluctuating during cabazitaxel therapy in patients with mCRPC. Because the prognosis of such patients was relatively good, the judgment to discontinue the cabazitaxel therapy after PSA rise followed by decrease should be made prudently.",
author = "Kent Kanao and Toshiki Ito and Kiyoshi Takahara and Ryosuke Ando and Takahiro Yasui and Ryoichi Shiroki and Hideaki Miyake and Makoto Sumitomo",
year = "2019",
month = "12",
day = "18",
doi = "10.1093/jjco/hyz110",
language = "English",
volume = "49",
pages = "1043--1048",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "11",

}

Prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer. / Kanao, Kent; Ito, Toshiki; Takahara, Kiyoshi; Ando, Ryosuke; Yasui, Takahiro; Shiroki, Ryoichi; Miyake, Hideaki; Sumitomo, Makoto.

In: Japanese journal of clinical oncology, Vol. 49, No. 11, 18.12.2019, p. 1043-1048.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer

AU - Kanao, Kent

AU - Ito, Toshiki

AU - Takahara, Kiyoshi

AU - Ando, Ryosuke

AU - Yasui, Takahiro

AU - Shiroki, Ryoichi

AU - Miyake, Hideaki

AU - Sumitomo, Makoto

PY - 2019/12/18

Y1 - 2019/12/18

N2 - BACKGROUND: The objective of this study was to categorize prostate-specific antigen (PSA) response during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) into different patterns and to investigate the prognostic impact of the PSA response patterns. METHODS: We reviewed data from patients with mCRPC who had been treated with cabazitaxel therapy at four institutions belonging to Tokai Urologic Oncology Research Seminar. Patients eligible for this study had received at least three cycles of cabazitaxel treatment at three- or four-week intervals. The PSA response patterns were categorized as primary resistance (PR), response (RE), stabilization (ST), and fluctuating (FL). The overall survival (OS) was compared among the patterns. RESULTS: Data from a total of 50 patients were analyzed in this study. The number of patients exhibiting PR, RE, ST and FL patterns were 18 (36%), 14 (28%), 12 (24%) and 6 (12%), respectively. The median (95% CI) OS of patients with PR and RE patterns was 10.7 (5.6-15.9) and 14.9 (6.8-23.0) months, respectively, and was not reached for patients with ST and FL patterns. The OS of patients with the FL pattern was significantly better than that of patients with PR (P = 0.012) and RE (P = 0.010) patterns. CONCLUSION: There were some patients whose PSA were fluctuating during cabazitaxel therapy in patients with mCRPC. Because the prognosis of such patients was relatively good, the judgment to discontinue the cabazitaxel therapy after PSA rise followed by decrease should be made prudently.

AB - BACKGROUND: The objective of this study was to categorize prostate-specific antigen (PSA) response during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) into different patterns and to investigate the prognostic impact of the PSA response patterns. METHODS: We reviewed data from patients with mCRPC who had been treated with cabazitaxel therapy at four institutions belonging to Tokai Urologic Oncology Research Seminar. Patients eligible for this study had received at least three cycles of cabazitaxel treatment at three- or four-week intervals. The PSA response patterns were categorized as primary resistance (PR), response (RE), stabilization (ST), and fluctuating (FL). The overall survival (OS) was compared among the patterns. RESULTS: Data from a total of 50 patients were analyzed in this study. The number of patients exhibiting PR, RE, ST and FL patterns were 18 (36%), 14 (28%), 12 (24%) and 6 (12%), respectively. The median (95% CI) OS of patients with PR and RE patterns was 10.7 (5.6-15.9) and 14.9 (6.8-23.0) months, respectively, and was not reached for patients with ST and FL patterns. The OS of patients with the FL pattern was significantly better than that of patients with PR (P = 0.012) and RE (P = 0.010) patterns. CONCLUSION: There were some patients whose PSA were fluctuating during cabazitaxel therapy in patients with mCRPC. Because the prognosis of such patients was relatively good, the judgment to discontinue the cabazitaxel therapy after PSA rise followed by decrease should be made prudently.

UR - http://www.scopus.com/inward/record.url?scp=85076876670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076876670&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyz110

DO - 10.1093/jjco/hyz110

M3 - Article

C2 - 31369101

AN - SCOPUS:85076876670

VL - 49

SP - 1043

EP - 1048

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 11

ER -